Table 1: Descriptive study of 54 psoriatic arthritis patients.
|
|
N or central tendency |
|
Females/males |
28/26 or 51.8%/48.1% |
|
Ethnic background Caucasians Afro descendants |
52/54 - 96.2% 2/54 - 3.7% |
|
Mean age (years) ± SD |
53.6 ± 11.0 |
|
Tobacco exposure (current and ex) |
28/54 - 51.8% |
|
Psoriatic arthritis subset (*) Oligoarticular Polyarticular Axial Distal interphalangeal- |
30/54 - 55.5% 14/54 - 25.9% 24/54 - 44.4% 5/54 - 9.2% |
|
Median Psoriatic arthritis duration (years) (IQR) |
4.0 (1.5-12.0) |
|
Median psoriasis duration (years) (IQR) |
11.0 (7.0-24.0) |
|
Median PASI (IQR) |
1.0 (0-4.8) |
|
Mean ASDAS-ESR ± SD |
3.16 ± 1.23 |
|
Mean ASDAS-CRP ± SD |
3.50 ± 1.47 |
|
Median ESR (mm) (IQR) |
26 (10-47) |
|
Median CRP (mg/dL) |
4.7 (2.0-8.2) |
|
Treatment |
|
|
Methotrexate |
28/54 - 51.8% |
|
Leflunomide |
11/54 - 20.3% |
|
Anti TNF-alpha |
18/54 - 33.3% |
|
Secuquinumab |
5/54 - 9.2% |
|
Ustequinumab |
1/54 - 1.8% |
(*)- 35 patients had combined forms.
SD: Standard Deviation; IQR: Interquartile Range; ASDAS: Ankylosing Spondylitis Disease Activity Score; ESR: Erythrocyte Sedimentation Rate; CRP: C Reactive Protein; PASI: Psoriasis Area Severity Index; TNF: Tumoral Necrosis Factor